Humoral and cellular immune response from first to fourth SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple sclerosis patients—a longitudinal cohort study
Low levels or absence of specific anti-RBD following vaccination, with a significant increase after breakthrough infections and boosted by the fourth vaccination. T-cell reactivity remained sustained and unaffected by breakthrough infections.
Authors
- Anna Christine Nilsson (ORCID: https://orcid.org/0000-0001-7885-8400)
- Keld‐Erik Byg (ORCID: https://orcid.org/0000-0003-4834-5457)
- Işık Somuncu Johansen (ORCID: https://orcid.org/0000-0002-2189-9823)
- Christian Nielsen (ORCID: https://orcid.org/0000-0002-5711-6595)
- Mike Bogetofte Barnkob (ORCID: https://orcid.org/0000-0002-5892-1174)
- Dorte Kinggaard Holm (ORCID: https://orcid.org/0000-0002-8156-7177)
- Tobias Sejbæk (ORCID: https://orcid.org/0000-0002-7682-2188)
- Frederik Novak
- Caroline Louise Stougaard (ORCID: https://orcid.org/0009-0008-1778-571X)
- Emil Birch Christensen (ORCID: https://orcid.org/0000-0002-0470-0210)
- Agnes Witt
Institutions
- University of Southern Denmark (DK)
- Odense University Hospital (DK)
- Hospital South West Jutland (DK)
- Regional Hospital Central Jutland (DK)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-09-05
- DOI
- https://doi.org/10.3389/fimmu.2024.1432348
- Citations
- 4
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 1.56
Funders
- Lundbeckfonden
- H. Lundbeck A/S